You are here

Merck weighing acquisition of Cubist for more than US$7b: sources

Deal, if announced, would be another multibillion-dollar health care transaction in a banner year for M&A

New York

DRUGMAKER Merck & Co is in talks to acquire the biopharmaceuticals company Cubist for more than US$7 billion, according to people briefed on the matter.

The deal, if announced, would represent another multibillion-dollar health care transaction in a banner year for